The rationale and future potential of angiogenesis inhibitors in neoplasia

Drugs

Volumn 58, Issue 1, 1999, Pages 17-38

  Gasparini, Giampietro ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTIBODY; BATIMASTAT; CAMPTOTHECIN; CGS 27023A; CM 101; CYTOTOXIC AGENT; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; INTERLEUKIN 12; IRINOTECAN; LEFLUNOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE INHIBITOR; PACLITAXEL; PENTOSAN POLYSULFATE; RETINOID; ROQUINIMEX; SURAMIN; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANOREXIA; ATAXIA; BRAIN DISEASE; BREAST CANCER; CANCER; CANCER GROWTH; CANCER INVASION; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MONITORING; DRUG TARGETING; ENDOTHELIUM CELL; GASTROINTESTINAL TOXICITY; GENE THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PROSTATE CANCER; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREMOR; UTERINE CERVIX CANCER; VERTIGO;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0032792360     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958010-00003     Document Type: Review

References (196)

1. 1. Chabner BA. Clinical strategies for cancer treatment: the role of drugs. In: Chabner BA, Collins JM, editors. Cancer chemotherapy. Principles and practice. Philadelphia: JB Lippincott Co, 1990: 1-15
2. 2. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Hinda Rosenthal Foundation award (lecture). Cancer Res 1993; 53: 747-54
3. 3. Gasparini G, Harris AL. Does improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur J Cancer 1994; 30A: 201-6
4. 4. Karp JE, Broder S. New directions in molecular medicine. Cancer Res 1994; 54: 653-65
5. 5. Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat Med 1995; 1: 309-20
6. 6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6
7. 7. Hunt BJ, Jurd KM. Endothelial cell activation: a central pathophysiological process. BMJ 1998; 316: 1328-9
8. 8. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-9
9. 9. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80
10. 10. Henn V, Slupsky JR, Grafe M, et al. CD 40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nat 1998; 391: 591-4
11. 11. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-45
12. 12. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31-6
13. 13. Rak J, Kerbel RS. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Rev 1996; 15: 231-6
14. 14. Hammersen F, Endrich B, Messner K. The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis. Int J Microcirc Clin Exp 1985; 4: 31-43
15. 15. Dvorak HF, Nagy JA, Dvorak JT, et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109
16. 1 for angiogenesis. Science 1994; 264: 569-71
17. 3 in neuroblastic tumors. Am J Pathol 1996; 148: 1423-34
18. 18. Kraling BM, Razon MJ, Boon LM, et al. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 1996; 148: 1181-91
19. 19. Burrows FJ, Derbyshire J, Tazzari PL, et al. Up regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1: 1623-34
20. 20. Takahashi K, Mulliken JB, Kozakewich HPW, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357-64
21. 21. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody tu H-and Y-antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994; 7: 82-90
22. 22. Terman BI, Dougher-Vermazen M. Biological properties of VEGF/VPF-receptors. Cancer Metastasis Rev 1996; 15: 159-63
23. 23. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-16
24. 24. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk 1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997; 89: 981-90
25. 25. Hanahan D, Folkman J. Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64
26. 26. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. In: Vande Woude GF, Klein G, editors. Advances in cancer research. San Diego (CA): Academic Press, 1996; 69: 135-74
27. 27. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4
28. 28. Folkman J. Clinical applications of research on angiogenesis. New Engl J Med 1995; 333: 1757-63
29. 29. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1989; 82: 4-6
30. 30. Folkman J. Angiogenesis and metastatic growth. Adv Oncol 1996; 12: 2-7
31. 31. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-8
32. 32. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
33. 33. Gasparini G. Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications? Crit Rev Oncol Hematol 1997; 26: 147-62
34. 34. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998; 4: 655-7
35. 35. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991; 51: 6180-4
36. 36. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4
37. 37. O'Reilly M, Rosenthal R, Sage EH, et al. The suppression of tumor metastases by a primary tumor. Surg Forum 1993; 44: 474-6
38. 38. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85
39. 39. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15: 39-48
40. 40. Gasparini G. Angiogenesis research up to 1996: a commentary on the state of art and suggestions for future studies. Eur J Cancer 1996; 32A: 2379-85
41. 3 during angiogenesis. J Clin Invest 1996; 98: 426-33
42. 42. Gasparini G, Harris AL. p53 and angiogenesis in neoplasia. In: Klijn JGM, editor. Prognostic and predictive value of p53. Scientific updates. I. European School of Oncology. Amsterdam: Elsevier Press BV, 1997: 115-30
43. 43. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-5
44. 44. Volpert O, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995; 36: 119-26
45. 45. Bouck N. p53 and angiogenesis. Biochim Biophys Acta 1996; 1287: 63-6
46. 46. Stellmach V, Volpert OV, Crawford SE, et al. Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. Eur J Cancer 1996; 32A: 2394-400
47. 47. Kieser A, Wiech HA, Brandner G, et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-9
48. 48. Rak J, Filmus J, Finkenzeller G, et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995; 14: 263-77
49. 49. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575-80
50. 50. Kaelin WG, Hiopoulus O, Lonergan KM, et al. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 1998; 243: 535-9
51. 51. Rosen EM, Goldberg ID. Regulation of angiogenesis by scatter factor. EXS 1997; 79: 193-208
52. 52. Sheibani N, Fraizer WA. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed N1H3T3. Cancer Lett 1996; 107: 45-52
53. 53. Mettouchi A, Cabon F, Montreau N, et al. SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts. EMBO J 1994; 13: 5668-78
54. 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A 1994; 91: 8856-9
55. 3. Cell 1996; 85: 683-93
56. 56. Gomis-RĀth FX, Maskos K, Betz M, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997; 389: 77-81
57. 57. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-5
58. 58. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1997; 99: 373-6
59. 59. Shatti SJ, Ginsberg MH. Integrin signalling in vascular biology. J Clin Invest 1997; 100: 1-5
60. 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22
61. 61. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75
62. 62. Kondo S, Yin D, Aoki T, et al. bcl-2 gene prevents apoptosis of basic fibroblast growth factor-deprived murine aortic endothelial cells. Exp Cell Res 1994; 213: 428-32
63. 63. Polunovsky VA, Wendt CH, Ingbar DH, et al. Induction of endothelial cell apoptosis by TNFα: modulation by inhibitors of protein synthesis. Exp Cell Res 1994; 214: 548-44
64. 64. Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in braf deficient mice. Nat Genet 1997; 16: 293-7
65. 65. Katoh O, Tauchi H, Kawaishi K, et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687-92
66. 66. Langley RE, Bump EA, Quartuccio SG, et al. Radiation-induced apoptosis in microvascular endothelial cells. Br J Cancer 1997; 75: 666-72
67. 67. Pollman MJ, Hall JL, Mann MJ, et al. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 1998; 4: 222-7
68. 68. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-53
69. 69. Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 1998; 95: 5579-83
70. 70. Guo NH, Krutch HC, Inman JK, et al. Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57: 1735-42
71. 71. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992-7
72. 72. Ferrara N. Natural killer cells, adhesion and tumor angiogenesis. Nat Med 1996; 2: 971-2
73. 73. Gabrilovich DL, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-103
74. 74. Adams DH, Yannelli JR, Newman W, et al. Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotipic and functional analysis. Br J Cancer 1997; 75: 1421-31
75. 75. Zimrin AB, Maciag T. Progress towards unifying hypothesis for angiogenesis. J Clin Invest 1996; 1359-97
76. 76. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975; 141: 427-39
77. 77. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982; 297: 307-12
78. 78. Folkman J, Ingber DE. Angiostatic steroids: method of discovery and mechanism of action. Ann Surg 1987; 206: 374-83
79. 79. Folkman J, Weisz PB, Joullié MH, et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989; 243: 1490-3
80. 80. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988; 59: 44-50
81. 81. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagallin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7
82. 82. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagallin parent. Biochem Biophys Res Commun 1991; 174: 1070-6
83. 83. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994; 69: 212-6
84. 84. Maier JAM, Delia D, Thorpe PE, et al. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 1997; 8: 238-44
85. 85. Abe J, Zhou W, Takuwa N, et al. A fumagallin-derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product, but not protein tyrosyl phosphorylalion or protooncogene expression in vascular endothelial cells. Cancer Res 1994; 54: 3407-12
86. 86. Tanaka T, Konno H, Matsuda I, et al. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995; 55: 836-9
87. 87. Mori S, Ueda T, Karatsu S, et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1995; 61: 148-52
88. 88. Konno H, Tanaka T, Kanai T, et al. Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 1996; 77: 1736-40
89. 80. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995; 36: 227-36
90. 90. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920-5
91. 91. Toi M, Yamamoto Y, Imazawa T, et al. Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 1993; 3: 525-8
92. 92. Teicher BA. A systems approach to cancer therapy. (Antiangiogenics + standard cytotoxics - mechanism(s) of interaction). Cancer Metastasis Rev 1996; 15: 247-72
93. 93. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-8
94. 94. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55: 1827-34
95. 95. Ching L-M, Xu Z-F, Gummer BH, et al. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 72: 339-43
96. 96. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990; 87: 6624-8
97. 97. Sheibani N, Frazier WA. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995; 92: 6788-92
98. 98. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994; 54: 6504-11
99. 99. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A 1998; 95: 6343-8
100. 100. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92: 10457-61
101. 121. Cancer Res 1995; 55: 5296-301
102. 102. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996; 93: 14765-70
103. 103. Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993; 69: 508-17
104. 104. Relf M, LeJeune S, Scott PAE, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-9
105. 105. Toi M, Gion M, Biganzoli E, et al. Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications. Angiogenesis 1997; 1: 71-83
106. 106. Okada A, Bellocq J-P, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT_MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A 1995; 92: 2730-4
107. 107. Hitraya EG, Tan EML, Rudnicka L, et al. Expression of extracellular matrix genes in adult human dermal microvascular endothelial cells and their regulation by heparin and endothelial cell mitogens. Lab Invest 1995; 73: 393-402
108. 108. Heppner KJ, Matrisian LM, Jensen RA, et al. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-82
109. 109. Giannelli G, Falk-Marzillier J, Schiraldi O, et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997; 277: 225-8
110. 110. Watson SA, Morris TM, Robinson G, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33
111. 111. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 1995; 6: 967-74
112. 112. Brooks PC, Silletti S, von Schalscha TL, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998; 92: 391-400
113. 113. Bertram JS, Kolonel LN, Meyskens Jr FL. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987; 47: 3012-31
114. 114. Emmanuelle DE, Liaudet-Coopman, Berchem GJ, et al. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin Cancer Res 1997; 3: 179-84
115. 115. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol 1996,149: 247-58
116. 116. Lingen MW, Polverini PJ, Bouck NP. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 1996; 74: 476-83
117. 117. Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995; 71: 655-9
118. 118. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-6
119. 119. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28
120. 120. Clapp C, Marthal JA, Guzman RC, et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993; 133: 1292-9
121. 121. Cao YH, Chen A, An SSA, et al. Kringle-5 of plasminogen is a novel inhibitor of endothelial-cell growth. J Biol Chem 1997; 272: 22924-8
122. 122. Singh RK, Gutman M, Bucana CD, et al. Interferons α and β down-regulate tho expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995; 92: 4562-6
123. 123. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104: 689-96
124. 124. Marx M, Perlmutter RA, Madri JA. Modulation of platelet derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 1994; 93: 131-9
125. 125. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci U S A 1995; 92: 7799-803
126. 126. Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 1991; 47: 230-5
127. 127. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994; 7: 2062-72
128. 128. Pierce DF, Gorska AE, Chytil A, et al. Mammary tumor suppression hy transformin growth factor β1 transgene expression. Proc Natl Acad Sci U S A 1995; 92: 4254-8
129. 129. Nanji AA, Tahan SR, Golding M, et al. Role of transforming growth factor-(BETA) 1 in inhibiting endothelial cell proliferation in experimental alcoholic liver disease. Am J Pathol 1996; 148: 739-47
130. 130. Frater-Schroder M, Risau W, Hallmann R, et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A 1987; 84: 5277-81
131. 131. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987; 329: 630-2
132. 132. Volpert OV, Tolsma SS, Pellerin S, et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995; 217: 326-32
133. 133. Li L, Yu G, Zhai Y, et al. A novel endothelial cell-specific negative regulator of angiogenesis [abstract no. 1852]. Proc Am Assoc Cancer Res 1998 39 New Orleans, 1998: 271
134. 134. Van Meir EG. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994; 8: 171-6
135. 135. Pepper MS, Ferrara N, Orci L, et al. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. J Cell Sci 1995; 108: 73-83
136. 136. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1: 120-2
137. 137. Gately S, Twardowski P, Stack SM, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996; 56: 4887-90
138. 138. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancel-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci U S A 1997; 94: 10868-72
139. 139. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997; 88: 801-10
140. 140. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors. Nat Med 1996; 2: 689-92
141. 141. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7
142. 142. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390: 335-6
143. 143 Bergers G, Javaherian K, Lo K-M et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-12
144. 144. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57: 81-6
145. 145. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-9
146. 146. O'Leary JJ, Shapiro KL, Ren CJ, et al. Anti-angiogenic effects of 9-amino-20 (s)-camptothecin (9 AC), topotecan (TTN), and camptosar (CPT-11) [abstract no. 296]. 10th NCI-EORTC Symposium on new drugs in cancer therapy; 1998 June 16-19; Amsterdam, 78
147. 147. Fan T-P D, Jaggar R, Bicknell R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995; 16: 57-66
148. 148. Huang X, Molema G, King S, et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-50
149. 149. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature Proc Natl Acad Sci U S A 1993; 90: 8996-9000
150. 150. Ziche M, Donnini S, Morbidelli L, et al. Linomide blocks angiogenesis by breast carcinoma VEGF transfectants. Br J Cancer 1998; 77: 1123-9
151. 151. Mauceri HJ, Hanna NN, Beckett MA. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-91
152. 152. Castronovo V, Belotti D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer 1996; 32A: 2520-7
153. 153. Brem S. Angiogenesis antagonists: current clinical trials. Angiogenesis 1998; 2: 9-20
154. 154. Kudelka AP, Verschracgen CF, Loyer E. Complele remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. New Engl J Med 1998; 338: 991-2
155. 155. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIK-I/KDR) that inhibits tryosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106
156. 3 [abstract no. 832]. Proc Amer Soc Clin Oncol: 1998 May 16-19: Los Angeles; 17: 215
157. 157. Folkman J. New directions in angiogenesis research [abstract no. 031]. 10th NCI-EORTC Symposium on new drugs in cancer therapy; 1998 Jun 16-9; Amsterdam, 9
158. 158. O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 1997; 15: 5-13
159. 159. Folkman J, Haundenschild CC, Zetter BR. Long-term culture of capillary endithelial cells. Proc Natl Acad Sci U S A 1979; 76: 5217-21
160. 160. Auerbach R, Kubai L, Knighton D, et al. A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 1974; 41: 391-4
161. 161. Grant DS, Tashiro K-I, Sequi-Real B, et al. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 1989; 58: 933-43
162. 162. Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998; 90: 587-96
163. 163. Gimbrone MAJ, Cotran R, Leapman S, et al. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52: 413-27
164. 164. Hanahan D. Heritable formation of pancreatic beta-cell tumors in transgenic mice harboring recombinant insulin/simian virus 40 oncogene. Nature 1985; 315: 115-22
165. 165. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 1996; 93: 2002-7
166. 166. Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst 1998; 90: 273-86
167. 167. Teicher BA, Alvarez Sotomayor E, Huang ZD, et al. β-cyclodextrin tetradecasulfate/tetrahydrocortisol + minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma. Cancer Chemother Pharmacol 1993; 33: 229-38
168. 168. Brem H, Gresser I, Grosfeld J, et al. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatric Surg 1993; 28: 1253-7
169. 169. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100
170. 170. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15
171. 171. Gasparini G, Presta M. Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation [editorial]. Ann Oncol 1996; 7: 441-4
172. 172. Salven P, MN̄enpN̄N̄H, Orpana A, et al. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647-51
173. 173. Dirix LY, Vermeulen PB, Pawinski A, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238-43
174. 174. Colomer R, Aparicio J, Montero S, et al. Low levels of basic fibroblast growth factor (hFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 1997; 76: 1215-20
175. 175. Vermeulen PB, Salven P, Benoy I, et al. Blood platelets and serum VEGP in cancer patients. Br J Cancer 1999; 79: 370-3
176. 176. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-47
177. 177. Jain RK, Schlenger K, Hockel M, et al. Quantitative angiogenesis assays: progress and problems. Nat Med 1997; 3: 1203-8
178. 178. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61
179. 179. Weinstat-Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994; 8: 401-7
180. 180. Gordon MS, Talpaz M, Margolin K, et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients (pts) with metastatic cancer [abstract no. 809]. Proc Amer Soc Clin Oncol ; 1998 May 16-19: Los Angeles; 17: 210
181. 181. Rosen LS, Kabbinavar F, Rosen P, et al. Phase I trial of SU5416, a novel angiogenesis inhibitor, in patients with advanced malignancies [abstract no. 290]. 10th NCI-EORTC Symposium on new drugs in cancer therapy; 1998 June 16-19; Amsterdam: 76
182. 182. Meredith Jr JE, Schwartz MA. Integrins, adhesion and apoptosis. Cell Biol 1997; 7: 146-50
183. 3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med 1998; 4: 408-14
184. 3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625-34
185. 185. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996; 32A: 2528-33
186. 186. Borsotti P, Rieppi M, Gatto C. Antiangiogenic activity of BAY 12-9566, an inhibitor of matrix metalloproteinases [abstract no. 281]. 10th NCI-EORTC symposium on new drugs in cancer therapy; 1998 June 16-19; Amsterdam: 74
187. 187. Singhal S, Mehta J, Eddlemon P, et al. Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) [abstract no. 1306]. Blood 1998; 92 (10 Suppl. 1): 318a
188. 188. Wadman M. Cancer 'cure' article stirs up hot debate. Nature 1998; 393: 104-5
189. 189. Marshall E. The roadblocks to angiogenesis blockers. Science 1998; 280: 996-7
190. 190. Harris AL. Are angiostatin and endostatin cures for cancer? Lancet 1998; 351: 1598-9
191. 191. Cimons M. A tale of two cancer drugs. Nat Med 1998; 4: 650
192. 192. Cohen J. Behind the headlines of endostatin's ups and downs. Science 1999; 283: 1250-1
193. 193. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell-lung carcinoma tumor-growth without morphological evidence of neoangiogenesis. Am J Pathol 1997; 151: 1417-23
194. 194. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995; 87: 1588-92
195. 195. Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'Angiogenesis progression' hypothesis. Eur J Cancer 1996; 32A: 2432-50
196. 196. Von Hoff DD. There are no had anticancer agents, only bad clinical trial designs. Twenty-first Richard and Hinda Rosenthal Foundation award lecture. Clin Cancer Res 1998; 4: 1079-86